Effective Luteinizing Hormone Drug Delivery by Nanocarriers in Hormonal Cancer Treatment

Abstract

The luteinizing hormone (LH) secretes mainly two types of hormone, that is, LH and follicle-stimulating hormone (FSH). The receptors of luteinizing hormone-releasing hormone (LHRH) are overexpression in the majority of different types of cancers, while their expression in healthy tissues, apart from pituitary cells, is limited. In the current scenario, modern research studies recommended that LHRH peptides can be employed to efficiently guide anticancer and imaging agent means visualizing the internal organs directly to cancerous cells. As a result, the number of these compounds in tumour tissue increases, while normal cells are spared unneeded exposure. Nanoparticles can be employed for targeting anticancer drugs in which it is anticipated that nanocarriers would deliver the drug at the unhealthy cancerous tissues via two mechanisms, i.e., passive or active mechanism. However, several nano-medicines have been formulated to improve the anticancer effect. Hence, synthesized nanoparticles could serve as a potential carrier with an advantage of improved biodegradability, biocompatibility, improved loading capacity, targeting ability, scalability, and stability.